Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi
Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals in a transaction that values the U
Over the past twelve months there has been significant advancements in cell gene therapy for inherited retinal dystrophy, with an FDA approval of Spark Therapeutics’ Voretigene – t
Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorde
After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days pr
